Home Stock

Stock Research: Camurus

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Camurus

STO:CAMX SE0007692850
35
  • Value
    1
  • Growth
    21
  • Safety
    Safety
    87
  • Combined
    13
  • Sentiment
    97
  • 360° View
    360° View
    35
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Camurus AB is a Sweden-based pharmaceutical and biotechnology company focused on specialty medicines for severe and chronic diseases. They operate in the pharmaceutical and biotechnology industries, developing products for opioid dependence, pain, cancer, and endocrine diseases. The company is based in Sweden and has legal entities in the US, Germany, UK, Finland, Norway, France, Australia, Spain, Denmark, Austria, and the Netherlands. In the last fiscal year, the company had a market cap of $4186 million, profits of $157 million, revenue of $169 million, and 256 employees.

more

ANALYSIS: With an Obermatt 360° View of 35 (better than 35% compared with alternatives), overall professional sentiment and financial characteristics for the stock Camurus are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half below and half above average for Camurus. The consolidated Sentiment Rank has a good rank of 97, which means that professional investors are more optimistic about the stock than for 97% of alternative investment opportunities. It also rates well regarding its financing structure, with the consolidated Safety Rank at 87 or better than 87% of its peers when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the stock is expensive and expects low growth. The consolidated Value Rank is only 1, meaning that the share price of Camurus is on the high side, compared with indicators such as revenues, profits, and invested capital. The company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth,and stock returns, with its Growth Rank at 21. ...read more

more
Strongest Rank Value
Weakest Rank Sentiment
Country Sweden
Industry Pharmaceuticals
Size Small
Website camurus.com
Index
Camurus stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 23-Apr-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
1 4 1 8
Growth
21 100 95 91
Safety
Safety
87 96 80 34
Sentiment
97 54 76 82
360° View
360° View
35 57 86 56
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
87 69 78 95
Opinions Change
50 50 72 50
Pro Holdings
n/a 45 53 64
Market Pulse
87 48 39 31
Sentiment
97 54 76 82
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
1 4 1 8
Growth
21 100 95 91
Safety Safety
87 96 80 34
Combined
13 69 72 37
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
19 3 5 31
Price vs. Earnings (P/E)
13 14 6 25
Price vs. Book (P/B)
25 3 5 12
Dividend Yield
1 1 1 1
Value
1 4 1 8
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
94 96 73 90
Profit Growth
37 98 100 78
Capital Growth
7 85 22 93
Stock Returns
24 86 100 20
Growth
21 100 95 91
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
83 92 90 77
Refinancing
55 25 27 36
Liquidity
94 100 79 8
Safety Safety
87 96 80 34

Similar Stocks

Discover high‑ranked alternatives to Camurus and broaden your portfolio horizons.

Ipsen

PAR:IPN
Country: France
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Richter Gedeon

BUD:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Industrivarden

STO:INDU A
Country: Sweden
Industry: Multi-Sector Holdings
Size: Medium
Full Stock Analysis

Faes Farma

MCE:FAE
Country: Spain
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

The value case is weak (expensive and low Growth Rank), but sentiment is strong and financing is safe. This scenario may indicate future growth not yet in current financials. This is a speculative choice for investors with a high-risk appetite who are betting on the positive sentiment and safe financing to sustain a long-term turnaround.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews